Cesca Therapeutics is a regenerative medicine company that develops, commercializes and markets a range of automated technologies for cell-based therapeutics. The Company’s device division, ThermoGenesis Corp., provides a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology. Cesca’s clinical development division is leveraging its proprietary AutoXpress technology platform to develop autologous stem cell-based therapies that address significant unmet needs in the immuno-oncology, vascular, cardiology and orthopedic markets.

Type
Public
HQ
Rancho Cordova, US
Founded
1986
Size (employees)
95 (est)
Cesca Therapeutics was founded in 1986 and is headquartered in Rancho Cordova, US
Report incorrect company information

Cesca Therapeutics Office Locations

Cesca Therapeutics has offices in Wuxi Shi, Rancho Cordova and Gurgaon
Rancho Cordova, US (HQ)
2711 Citrus Rd
Gurgaon, IN (HQ)
857 Udyog Vihar Phase V
Wuxi Shi, CN
800 Jie Fang Dong Lu
Show all (3)
Report incorrect company information

Cesca Therapeutics Financials and Metrics

Cesca Therapeutics Financials

Cesca Therapeutics's revenue was reported to be $11.93 m in FY, 2016 which is a 25.6% decrease from the previous period.
USD

Revenue (Q1, 2018)

3.1 m

Gross profit (Q1, 2018)

(6.8 m)

Gross profit margin (Q1, 2018), %

(221%)

Net income (Q1, 2018)

(2.6 m)

EBIT (Q1, 2018)

(2.4 m)

Market capitalization (15-Jun-2018)

10.4 m

Closing share price (15-Jun-2018)

0.5

Cash (31-Dec-2017)

3.5 m
Cesca Therapeutics's current market capitalization is $10.4 m.
Annual
USDFY, 2014FY, 2015FY, 2016

Revenue

16 m16 m11.9 m

Revenue growth, %

0%(26%)

Cost of goods sold

10.1 m11.3 m9.2 m

Gross profit

5.9 m4.7 m2.7 m
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Revenue

3.7 m4.6 m4 m2.8 m3.3 m2.8 m3.8 m4 m3.3 m3.1 m

Cost of goods sold

2.5 m3.1 m2.9 m2.5 m2.3 m2.4 m2.4 m2.5 m1.9 m9.9 m

Gross profit

1.2 m1.5 m1.1 m367 k1 m408 k1.4 m1.6 m1.4 m(6.8 m)

Gross profit Margin, %

32%33%28%13%31%14%37%39%42%(221%)
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Cash

14.8 m3.4 m5.8 m3.5 m

Accounts Receivable

6.2 k

Inventories

524 m

Current Assets

25.3 m13.3 m12.8 m11.5 m
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Cash

10.7 m8.4 m4.8 m6.6 m2.9 m7.2 m5.6 m4.9 m3.8 m2.5 m

Accounts Receivable

258 k

Inventories

5.9 m5.2 m5 m4 m4 m3.5 m282 k

Current Assets

21.5 m18.4 m15.7 m14.3 m10.7 m15.1 m12.2 m10.9 m10.6 m10.3 m
Annual
USDFY, 2014FY, 2015FY, 2016

Net Income

(8.6 m)(14.9 m)(18.6 m)

Depreciation and Amortization

993 k1.4 m1.2 m

Inventories

6.4 k42.1 k

Accounts Payable

(2.4 m)
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Net Income

(3.3 m)(4.4 m)(4.8 m)(3.4 m)(624 k)(10.9 m)(22.4 m)(3.4 m)(2.1 m)

Inventories

5.9 m5.2 m5 m4 m4 m3.5 m

Accounts Payable

3 m3.2 m4.7 m5.7 m4.4 m3.3 m1.8 m2.1 m1.9 m
USDY, 2017

Revenue/Employee

32.3 k

Financial Leverage

1.5 x
Show all financial metrics

Cesca Therapeutics Operating Metrics

FY, 2016

Patents Issued

25
Show all operating metrics
Report incorrect company information

Cesca Therapeutics Online and Social Media Presence

Embed Graph
Report incorrect company information